Claims
- 1. A method of detecting analytes, the method comprising associating one or more reporter carriers with one or more target samples, wherein the reporter carrier comprises a specific binding molecule, a carrier, and a plurality of decoding tags, and
detecting the decoding tags.
- 2. The method of claim 1, wherein the carrier is selected from the group consisting of liposomes, microparticles, nanoparticles, virons, phagmids, and branched polymer structures.
- 3. The method of claim 1, wherein the carrier is a liposome or microbead.
- 4. The method of claim 3, wherein the liposomes are unilamellar vesicles.
- 5. The method of claim 4, wherein the vesicles have an average diameter of 150 to 300 nanometers.
- 6. The method of claim 3, wherein the liposome has an internal diameter of 200 nanometers.
- 7. The method of claim 1, wherein the carrier is a dendrimer.
- 8. The method of claim 7, wherein the dendrimer is contacting a macromolecule selected from the group consisting of DNA, RNA, and PNA.
- 9. The method of claim 8, wherein the macromolecule is an oligonucleotide between 20 and 300 nucleotides in length.
- 10. The method of claim 1, wherein the specific binding molecule is selected from the group consisting of antibodies, ligands, binding proteins, receptor proteins, haptens, aptamers, carbohydrates, synthetic polyamides, and oligonucleotides.
- 11. The method of claim 1, wherein the specific binding molecule is a binding protein.
- 12. The method of claim 11, wherein the binding protein is a DNA binding protein.
- 13. The method of claim 11, wherein the DNA binding protein contains a motif selected from the group consisting of a zinc finger motif, leucine zipper motif, and helix-turn-helix motif.
- 14. The method of claim 1, wherein the specific binding molecule is an oligonucleotide.
- 15. The method of claim 14, wherein the oligonucleotide is between 10 and 40 nucleotides in length.
- 16. The method of claim 14, wherein the oligonucleotide is between 16 and 25 nucleotides in length.
- 17. The method of claim 14, wherein the oligonucleotide is a peptide nucleic acid.
- 18. The method of claim 14, wherein the oligonucleotide forms a triple helix with the target sequence.
- 19. The method of claim 14, wherein the oligonucleotide comprises a psoralen derivative capable of covalently attaching the oligonucleotide to the target sequence.
- 20. The method of claim 1, wherein the specific binding molecule is an antibody.
- 21. The method of claim 20, wherein the antibody binds a protein.
- 22. The method of claim 1, wherein the decoding tags are selected from the group consisting of oligonucleotides, carbohydrates, synthetic polyamides, peptide nucleic acids, antibodies, ligands, proteins, haptens, zinc fingers, aptamers, mass labels, and any combination of these.
- 23. The method of claim 1, wherein the decoding tags are peptide nucleic acids.
- 24. The method of claim 1, wherein the decoding tags are capable of hybridizing specifically to an oligonucleotide reporter tag.
- 25. The method of claim 24, wherein the length of the oligonucleotide reporter tag is between 10 and 35 nucleotides long.
- 26. The method of claim 24, wherein the length of the oligonucleotide reporter tag is between 15 and 20 nucleotides long.
- 27. The method of claim 1, wherein the decoding tags are capable of being detected by a method selected from the group consisting of nuclear magnetic resonance, electron paramagnetic resonance, surface enhanced raman scattering, surface plasmon resonance, fluorescence, phosphorescence, chemiluminescence, resonance raman, microwave, mass spectrometry, mass spectrometry electrophoresis chromatography, and any combination of these.
- 28. The method of claim 1, wherein the decoding tags are capable of being detected through MALDI-TOF spectroscopy.
- 29. The method of claim 1, wherein the specific binding molecule and the carrier are covalently linked.
- 30. The method of claim 1, wherein the carrier and the decoding tags are covalently linked.
- 31. The method of claim 30, wherein the specific binding molecule and the carrier are covalently linked.
- 32. The method of claim 1, wherein the specific binding molecule comprises a first oligonucleotide and the carrier comprises a second oligonucleotide which can hybridize to the first oligonucleotide.
- 33. The method of claim 32, wherein the first oligonucleotide is conjugated to an antibody which binds a protein.
- 34. The method of claim 1, wherein the decoding tags are isobaric decoding tags.
- 35. The method of claim 34, wherein a plurality of reporter carriers are associated with one or more target samples, wherein the decoding tags of each reporter carrier are different.
- 36. The method of claim 35, wherein the all of the decoding tags of all of the reporter carriers have the same mass-to-charge ratio.
- 37. The method of claim 36, wherein the decoding tags are altered by altering their mass, charge, or both, wherein the altered forms of the decoding tags are distinguished via differences in the mass-to-charge ratio of the altered forms of the decoding tags.
- 38. A composition for detecting an analyte comprising a specific binding molecule, a carrier, and a plurality of decoding tags.
- 39. The composition of claim 38, wherein the carrier is selected from the group consisting of liposomes, microparticles, nanoparticles, virons, phagmids, and branched polymer structures.
- 40. The composition of claim 38 wherein the carrier is a liposome.
- 41. The composition of claim 40, wherein the liposomes are unilamellar vesicles.
- 42. The composition of claim 41, wherein the vesicles have an average diameter of 150 to 300 nanometers.
- 43. The composition of claim 40, wherein the liposome has an internal diameter of 200 nanometers.
- 44. The composition of claim 38, wherein the carrier is a dendrimer.
- 45. The composition of claim 44, wherein the dendrimer is contacting a macromolecule selected from the group consisting of DNA, RNA, and PNA.
- 46. The composition of claim 45, wherein the macromolecule is an oligonucleotide between 20 and 300 nucleotides in length.
- 47. The composition of claim 38, wherein the specific binding molecule is selected from the group consisting of antibodies, ligands, binding proteins, receptor proteins, haptens, aptamers, carbohydrates, synthetic polyamides, and oligonucleotides.
- 48. The composition of claim 38, wherein the specific binding molecule is a binding protein.
- 49. The composition of claim 48, wherein the binding protein is a DNA binding protein.
- 50. The composition of claim 48, wherein the DNA binding protein contains a motif selected from the group consisting of a zinc finger motif, leucine zipper motif, and helix-turn-helix motif.
- 51. The composition of claim 38, wherein the specific binding molecule is an oligonucleotide.
- 52. The composition of claim 51, wherein the oligonucleotide is between 10 and 40 nucleotides in length.
- 53. The composition of claim 51, wherein the oligonucleotide is between 16 and 25 nucleotides in length.
- 54. The composition of claim 51, wherein the oligonucleotide is a peptide nucleic acid.
- 55. The composition of claim 51, wherein the oligonucleotide forms a triple helix with the target sequence.
- 56. The composition of claim 55, wherein the oligonucleotide comprises a psoralen derivative capable of covalently attaching the oligonucleotide to the target sequence.
- 57. The composition of claim 38, wherein the specific binding molecule is an antibody.
- 58. The composition of claim 57, wherein the antibody binds a protein.
- 59. The composition of claim 38, wherein the decoding tags are selected from the group consisting of oligonucleotides, carbohydrates, synthetic polyamides, peptide nucleic acids, antibodies, ligands, proteins, haptens, zinc fingers, aptamers, mass labels, and any combination of these.
- 60. The composition of claim 38, wherein the decoding tags are peptide nucleic acids.
- 61. The composition of claim 38, wherein the decoding tags are capable of hybridizing specifically to an oligonucleotide reporter tag.
- 62. The composition of claim 61, wherein the length of the oligonucleotide reporter tag is between 10 and 35 nucleotides long.
- 63. The composition of claim 61, wherein the length of the oligonucleotide reporter tag is between 15 and 20 nucleotides long.
- 64. The composition of claim 38, wherein the decoding tags are capable of being detected by a method selected from the group consisting of nuclear magnetic resonance, electron paramagnetic resonance, surface enhanced raman scattering, surface plasmon resonance, fluorescence, phosphorescence, chemiluminescence, resonance raman, microwave, mass spectrometry, mass spectrometry electrophoresis chromatography, and any combination of these.
- 65. The composition of claim 38, wherein the decoding tags are capable of being detected through MALDI-TOF spectroscopy.
- 66. The composition of claim 38, wherein the specific binding molecule and the carrier are covalently linked.
- 67. The composition of claim 38, wherein the carrier and the decoding tags are covalently linked.
- 68. The composition of claim 67, wherein the specific binding molecule and the carrier are covalently linked.
- 69. The composition of claim 38, wherein the specific binding molecule comprises a first oligonucleotide and the carrier comprises a second oligonucleotide which can hybridize to the first oligonucleotide.
- 70. The composition of claim 69, wherein the first oligonucleotide is conjugated to an antibody which binds a protein.
- 71. The composition of claim 38, wherein the decoding tags are isobaric decoding tags.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. Provisional Application No. 60/201,963, filed May 5, 2000, and U.S. Provisional Application 60/224,939, filed Aug. 11, 2000. Application Ser. No. 60/201,963, filed May 5, 2000, and Application No. 60/224,939, filed Aug. 11, 2000, are hereby incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60201963 |
May 2000 |
US |
|
60224939 |
Aug 2000 |
US |